Protazine

Quick links to important sections

Protazine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Protazine

Property Description
Active Ingredient Promethazine Hydrochloride
Form Oral tablets, solutions, rectal suppositories
Pharmacological Class First-generation H₁ Antihistamine
Common Properties Antihistamine, Sedative, Antiemetic
Chemical Class Phenothiazine derivative

Protazine is a prescription medication containing the active ingredient promethazine hydrochloride, which is pharmacologically classified as a first-generation H₁ receptor antagonist. It is a derivative of the phenothiazine chemical class, setting it apart from many newer anti-allergy drugs due to its pronounced effects on the central nervous system.

This medication is available in several forms for different administration routes, including oral tablets and solutions, as well as specialized forms like rectal suppositories. The versatility of its forms allows it to be used in various settings, often where a sedative effect is desired alongside its primary action. Promethazine's specific pharmacological profile is widely supported by clinical literature, confirming its established role as a highly effective histamine blocker.

Promethazine is classified within the group of sedative antihistamines. This classification underscores that while it primarily relieves allergy-related discomfort, it is also therapeutically recognized for its distinct sedative and antiemetic (anti-nausea) properties. Protazine's long history since its development in the 1940s highlights its unique and enduring position in therapeutic medicine due to its comprehensive pharmacological action.

Regulatory References

  1. MedlinePlus source

What side effects are possible with Protazine?

Possible Side Effects and Safety Information

The safety profile of Protazine (promethazine) is derived strictly from official regulatory labeling, organizing adverse events by frequency and the body system affected. The most frequently documented effects are related to the central nervous system (CNS) and anticholinergic activity, which are classified as common.


System-Based Adverse Reactions

Adverse reactions are officially reported across several system-organ classes, with drowsiness (somnolence) and sedation being the most prominent. Other common reactions include anticholinergic effects like dry mouth and blurred vision, alongside dizziness and gastrointestinal disturbances such as nausea, vomiting, and constipation.


Serious Adverse Reactions and Key Constraints

Official documents highlight several serious and potentially fatal adverse reactions. A Boxed Warning is issued for the risk of respiratory depression, particularly underscoring the contraindication for all pediatric patients younger than two years of age due to this high risk. Other serious reactions documented include the rare occurrence of Neuroleptic Malignant Syndrome (NMS) and severe tissue injury (e.g., necrosis) associated with parenteral administration. Protazine may also lower the seizure threshold, requiring caution in relevant patient populations.


Population and Activity Safety Notes

Beyond the pediatric contraindication, older adults (geriatric patients) are noted to be more susceptible to CNS side effects like sedation and confusion. Due to the high incidence of drowsiness, the medication may impair the mental and physical abilities required for the performance of hazardous tasks, such as driving or operating heavy machinery.

Overdose and Emergency Response

Protazine Overdose and When to Seek Help

Protazine (promethazine), a sedating antihistamine, can cause serious effects if taken in doses exceeding the prescribed limits. An overdose can lead to severe central nervous system depression or, paradoxically, hyperexcitation. Children are particularly susceptible to severe symptoms and neurotoxicity.

Signs of Potential Overdose

Overdose symptoms can include a range of effects due to Protazine's mechanism of action. Immediate emergency medical attention is required if any of these signs appear:

  • Central Nervous System Effects: Severe drowsiness, unresponsiveness or coma, seizures, confusion, agitation, or hallucinations.
  • Cardiovascular Signs: Very low blood pressure (hypotension) and a rapid or irregular heartbeat (tachycardia, arrhythmias).
  • Respiratory Issues: Slowed, shallow, or troubled breathing, which may progress to respiratory depression.
  • Anticholinergic Symptoms: Dilated pupils, flushed skin, dry mouth, or difficulty urinating.

When to Seek Emergency Help

If you suspect an overdose on Protazine, call for emergency medical assistance immediately. Do not wait for symptoms to worsen. Be ready to provide the name of the drug, the estimated amount taken, and the time the ingestion occurred. Overdose management involves supportive care, including monitoring vital signs, maintaining the airway, and treating symptoms like seizures or severe blood pressure changes in a hospital setting. Prompt intervention is crucial for a positive outcome.

Therapeutic Uses of Protazine

Protazine: Main Uses and Benefits

Protazine (promethazine) is used across several domains where symptomatic relief is needed, particularly in contexts marked by heightened patient distress or functional strain. It offers supportive therapeutic benefit by managing challenging symptom clusters. The use of promethazine is consistent with established therapeutic contexts.


Symptomatic Relief for Allergic Conditions

Protazine is commonly used across conditions presenting with acute or recurrent manifestations of allergy. It helps address symptom clusters that may become intense or disruptive, such as urticaria (hives), persistent pruritus (itching), sneezing, and runny nose. The medication generally may contribute to improved comfort during periods of heightened allergic symptoms. The main categories of use include symptomatic management of perennial and seasonal allergic rhinitis, allergic conjunctivitis, urticaria, and angioedema.

“Protazine is considered relevant for its role in helping to ease pronounced itching associated with allergic skin conditions and may support periods of rest.”


Management of Nausea, Vomiting, and Short-Term Sedation

This medication is applied across domains where additional symptomatic support is needed for managing nausea and active vomiting arising from various causes, including motion sickness and postoperative discomfort. Furthermore, Protazine is used in areas where short-term symptom management is appropriate to address symptoms of increased neurological activity, such as restlessness or agitation, supporting the patient during difficult episodes by easing distress and assisting with symptomatic management.


Quick Fact: Relief for Acute Discomfort
Protazine supports the management of symptoms that interfere with daily functioning during acute symptomatic episodes, particularly related to motion sickness and severe itching, which often disrupt daily stability.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Protazine — Official Regulatory Information

The eligibility profile for Protazine (promethazine) is defined by official governmental regulations that establish absolute prohibitions and conditional use requirements, focusing on age and specific pre-existing health conditions.

Eligibility Scope Regulatory Status
Populations for whom use is allowed Adults, adolescents, and pediatric patients 2 years of age and older.
Populations for whom use is not recommended Pregnant or breastfeeding women, and older adults (use with caution recommended due to increased sensitivity).
Populations for whom use is contraindicated Pediatric patients less than 2 years of age; patients in a comatose state or suffering from severe CNS depression; individuals known to be hypersensitive to promethazine or other phenothiazines.

Age-Related Eligibility Rules

  • Infants (Under 2 years): Use is absolutely contraindicated due to the potential for fatal respiratory depression.
  • Children (Under 6 years in some regions): Oral forms are contraindicated in children under 6 years of age in specific regulatory regions (e.g., Australia, New Zealand).
  • Older Adults (65+): Use requires caution because these patients may be more sensitive to the drug's effects and are more likely to have age-related organ impairment.

Condition-Specific Eligibility Rules

Official labeling requires caution or avoidance in patients with certain health conditions, particularly those affected by the drug's potent anticholinergic or CNS depressant properties:

  • Respiratory Status: Contraindicated for treating lower respiratory tract symptoms (including asthma). Use should be avoided in patients with compromised respiratory function (e.g., COPD, sleep apnea).
  • Anticholinergic Risk: Use with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, pyloroduodenal obstruction, or bladder-neck obstruction.
  • Other Risks: Use with caution in persons with seizure disorders, cardiovascular disease, or bone-marrow depression.

Connection to the Overall Eligibility Profile

Regulatory documents strictly define who can and cannot use Protazine by establishing absolute non-eligibility for infants under the age of two, based on the documented risk of fatal respiratory depression. Eligibility is also prohibited for patients in a severely sedated or comatose state and those with a history of phenothiazine allergy. For eligible populations, use is restricted by specific pre-existing anticholinergic-risk comorbidities, which necessitate conditional use or avoidance as explicitly stated in the regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Protazine (promethazine hydrochloride) has officially documented interaction patterns that establish specific administration requirements and prohibitions, strictly detailed in regulatory prescribing information. The profile is defined by pharmacokinetic and pharmacodynamic interactions.


Pharmacodynamic and Contraindicated Interactions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, as this combination intensifies anticholinergic and CNS depressant effects, and increases the risk of hypotension. Protazine may increase, prolong, or intensify the sedative action when combined with other CNS depressants, including alcohol and opioid analgesics. Use with Anticholinergics may lead to potentiated effects. Furthermore, Protazine may block the alpha effects of Epinephrine (Adrenaline), potentially resulting in severe hypotension.


Pharmacokinetic and Timing Restrictions

Protazine is classified as a moderate inhibitor of the CYP2D6 enzyme. Co-administration with other medicines metabolized by this pathway may increase the plasma concentrations of the co-administered drug. For Beta Blockers, concurrent use may increase the plasma concentrations of both agents due to inhibition of metabolism. Timing separation is required for certain non-drug substances: Protazine must be discontinued at least 72 hours before allergen skin testing. Additionally, gastro-intestinal agents (aluminum, magnesium, or calcium salts) should not be taken at the same time to avoid reduced absorption of Protazine.

Mechanism of Action

Mechanism of Action

Protazine (promethazine) acts via multiple-receptor antagonism, which defines its broad physiological actions. It functions primarily as an antagonist at peripheral and central Histamine H1 Receptors but also blocks Muscarinic Cholinergic Receptors (mAChR), Dopamine D2 Receptors, and alpha1-Adrenergic Receptors.

Due to its high lipophilicity, the molecule easily crosses the blood-brain barrier, allowing it to disrupt central arousal pathways. Antagonism of central H1, cholinergic, and alpha1-adrenergic receptors suppresses multiple ascending systems, leading to a notable reduction in overall neuronal excitability. This mechanistic cascade establishes a state of Central Nervous System (CNS) depression and altered arousal.

The mechanism also targets the neurological inputs that activate the emetic center. By blocking D2 and H1 receptors in the Chemoreceptor Trigger Zone (CTZ) and inhibiting H1/muscarinic signaling within the vestibular pathways, the drug modulates a neurological reflex arc. This action inhibits the signaling pathways leading to the activation of the brain's emetic center.

Dosage and Administration Information

How Protazine is Used: Official Administration Guidelines

Protazine (promethazine hydrochloride) is administered according to specific, officially established protocols that define the route, dosage, and frequency of use. These instructions ensure proper administration across various clinical needs.


Approved Administration Routes and Forms

This medication is approved for several routes, including oral (as tablets, solutions, or syrups), rectal (via suppositories), and parenteral administration through Intramuscular (IM) injection or, in certain controlled settings, Intravenous (IV) injection. Official labeling strictly prohibits administration by the subcutaneous or intra-arterial routes.


Official Dosing and Frequency Patterns

Dosing schedules are defined by the specific use context. For the management of allergic symptoms, the typical adult regimen may be a single 25 mg dose taken at bedtime, or smaller doses (e.g., 6.25 mg to 12.5 mg) taken multiple times throughout the day. For the treatment of acute nausea or vomiting, the initial dose is generally 25 mg, followed by 12.5 mg to 25 mg every 4 to 6 hours as needed.


Administration Requirements and Age-Specific Rules

Oral Protazine may be consumed with food, water, or milk to help minimize potential stomach irritation. Parenteral administration has specific procedural constraints: deep IM injection is the preferred route. If given intravenously, the solution must be diluted to a specified concentration (e.g., leq 1 mg/mL) and infused slowly at a rate not exceeding 25 mg/minute into a large vein. Protazine is contraindicated for use in children less than 2 years of age; for patients 2 years and older, use must adhere to the lowest effective dose as per official guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

Studies have investigated whether Protazine may impact symptoms in patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). Research explored the drug in the context of inflammatory pathways associated with these conditions.

  • In clinical trials, researchers tracked symptom data, with changes often noted across the initial study period.
  • Studies examined the duration of observed changes in joint pain and swelling.
  • The primary outcome measures included the American College of Rheumatology (ACR) response criteria, which assessed changes in the number of swollen and tender joints.

Duration of Effect and Long-term Monitoring

Studies have contributed to the evidence base regarding the drug's effects. Data from clinical trials has been utilized to understand the potential for sustained changes in disease activity over time.

  • Long-term monitoring of events in adults was conducted in studies. Data collection occurred in open-label extension studies lasting up to five years.
  • Studies noted specific considerations for individuals with severe liver disease, which were part of the trial design.

Research into Combination Therapy

Research has explored whether combining this treatment with physical therapy may influence patient outcomes.

  • A randomized trial evaluated the impact of adding a structured physical therapy regimen to the drug treatment.
  • Researchers examined if the combination resulted in differences in functional capacity (measured by the Health Assessment Questionnaire-Disability Index, or HAQ-DI) compared to the drug alone.

Key Studies & References ACR Guidelines for the Management of Rheumatoid Arthritis: Treatment with Biologic and Targeted Synthetic DMARDs

Frequently Asked Questions (FAQ)

Common questions about Protazine (FAQ)


Q: Is Protazine the same kind of drug as [Similar Drug Name]?

A: Protazine is formally classified as a first-generation H₁ antihistamine that is derived from the phenothiazine chemical class. Official documents describe its pharmacological actions as having prominent sedative (sleep-inducing), anti-nausea, and anticholinergic effects, which sets it apart from other types of antihistamines.


Q: How quickly does Protazine typically start working?

A: According to official product information, the clinical effects of Protazine are generally noted relatively quickly. Effects are typically apparent within 20 minutes after taking it by mouth, and they may persist for four to six hours, though they can sometimes last up to 12 hours.


Q: Do all people who take Protazine experience side effects?

A: The official documentation lists a range of potential adverse reactions that have been reported by people taking the medication. However, it does not state that all individuals who use Protazine will experience side effects. Regulatory documents indicate that individual experiences with side effects can vary.


Q: What if I forget to take a dose of Protazine?

A: General drug information suggests that if you realize you have missed a dose, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, the missed dose is often skipped to avoid taking excess medication.


Q: How long is Protazine generally taken for?

A: The duration of use is not fixed and depends on the specific condition being treated, as documented in official prescribing information. For temporary issues like motion sickness or acute nausea, treatment may only involve a few doses. For certain allergic conditions, official administration patterns may involve longer use periods, sometimes taken once daily.


Q: What happens when you stop taking Protazine?

A: Official health guidance suggests that if Protazine has been taken regularly for an extended period, suddenly stopping the medication may lead to temporary symptoms. These discontinuation effects may include symptoms like dizziness, sweating, a fast heart rate, or difficulty sleeping. Discontinuation is a topic for which official guidance may be available.


Q: Does Protazine cause changes in weight?

A: Official regulatory documents, particularly from post-marketing surveillance, have noted that weight gain has been reported in association with the use of this class of medication, the phenothiazine derivatives. This is a potential side effect documented in official safety information.


Q: What if I experience unusual mood changes while taking Protazine?

A: Official adverse reaction reports include various changes in mental state, such as confusion, disorientation, excitement, agitation, and euphoria. It is also documented that children, in particular, may sometimes experience paradoxical reactions like increased excitability or nightmares.


Q: Is Protazine available as a generic medicine?

A: Yes, Protazine is a well-established medication and is widely available globally as a generic drug. It is sold under its chemical name, promethazine hydrochloride, in addition to various brand names.


Q: What is the official guidance on using Protazine during pregnancy?

A: Official guidance notes that the use of this medication during pregnancy is not generally recommended by regulators. Official prescribing information documents a possible risk that if administered close to delivery, Protazine may affect platelet function in the newborn infant, and the risks must be considered.


Q: Can Protazine be used for conditions other than its main approved use?

A: The use of Protazine is officially limited to the specific indications for which it has received regulatory approval from government agencies. These approved uses include treating allergic conditions, motion sickness, nausea/vomiting, and and as a sedative. The official labeling does not support its use outside of these defined indications.


Q: Is it normal to feel a bit nauseous when first starting Protazine?

A: Regulatory documents list nausea and vomiting as known and documented adverse reactions associated with Protazine. While the term 'normal' is not used in official texts, it is acknowledged that these gastrointestinal effects can occur, particularly when therapy is initiated.


Q: Does Protazine need to be taken at a specific time of day?

A: The timing of the dose depends on the reason it is being prescribed, according to official administration guidelines. For instance, when treating allergic conditions, a single dose is often recommended at bedtime due to the medication's potent sedative effect. For motion sickness, the first dose is typically recommended 30 to 60 minutes before travel begins.


Q: Are there different strengths or versions of Protazine available?

A: Yes, Protazine is manufactured in multiple official dosage forms and strengths. These include oral tablets (in different strengths), oral liquid solutions, rectal suppositories, and specific concentrations for injection (parenteral solutions).


Q: What type of research evidence supports the use of Protazine?

A: The drug’s approved uses are supported by research that establishes its role as a reliable H₁ receptor blocking agent that produces sedative and antiemetic (anti-nausea) effects. This evidence aligns with its long history of clinical use for these specific indications as recognized by regulatory bodies.


Q: What is the required monitoring or testing needed while on Protazine?

A: While routine blood testing is not generally required for everyone taking Protazine, official warnings note that caution is advised in patients with pre-existing bone-marrow depression. Because certain rare blood disorders have been reported, official guidance indicates caution and potential for monitoring in relevant patient populations.


Q: Does Protazine affect blood pressure?

A: Official adverse reaction reports list documented effects on the cardiovascular system. These include reports of both increased and decreased blood pressure (hypotension or hypertension) and changes in heart rate, such as a fast heart rate (tachycardia) or a slow heart rate (bradycardia).


Q: Is Protazine considered a 'new' drug or has it been around for a while?

A: Protazine is a long-established medication. It was originally synthesized and documented in 1947, classifying it as a classic, well-known phenothiazine derivative that has been used therapeutically for decades.


Q: How does Protazine affect the body?

A: Protazine primarily works by blocking histamine and acetylcholine receptors, which are widely distributed throughout the body. The general effects include reducing allergic symptoms, inhibiting the body's nausea reflex, and causing anticholinergic effects like dry mouth and blurred vision.


Q: What are the differences between how Protazine is used in different countries?

A: Official regulatory guidance can vary between different nations. For instance, certain regulatory bodies outside the US have additional prescribing constraints, such as contraindicating the oral forms for use in children under 6 years of age due to concerns about central nervous system side effects in that population.


Q: Is there any research about Protazine in specific patient groups, like those with diabetes?

A: While specific, dedicated trials on patient groups like those with diabetes are not typically the focus of the main drug labeling, official adverse reaction data includes reports of an increase in glucose tolerance in patients taking Protazine. This suggests a known metabolic effect.

How should Protazine be stored and disposed of?

How to Store and Dispose of Protazine

Protazine (promethazine hydrochloride) tablets and oral solutions must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be protected from light and stored in a tightly closed, light-resistant container to prevent degradation.

Rectal suppositories require distinct storage and must be kept in a refrigerator between 2 C and 8 C. All forms must be kept out of the reach of children.

Do not use liquid if it has developed color or contains a precipitate. Unused or expired medication should not be flushed down the toilet. Dispose of product through a medicine take-back program or by mixing with an undesirable substance and sealing it in a plastic bag before placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Protazine found in:

A-Z Index: